Specialty Drug


PIRFENIDONE is used to treat idiopathic pulmonary fibrosis. Compare antifibrinolytics.

Esbriet Latest News

Get the latest updates on this drug from the GoodRx medical team

Ofev and Esbriet: New Treatments for Idiopathic Pulmonary Fibrosis

The GoodRx Pharmacist - November 05, 2014

Both Ofev (nintedanib) and Esbriet (pirfenidone) were approved by the FDA on October 15, 2014 for the treatment of idiopathic pulmonary fibrosis (IPF). This is big for anyone suffering from this condition—these are the first two medications to be proven to slow the progression of IPF, which is usually a fatal disease.

First, what is idiopathic pulmoary fibrosis?

Idiopathic pulmonary fibrosis (IPF) is a condition where the tissue in the lungs thickens and turns into scar tissue over time. See More

GoodRx is not sponsored by or affiliated with any of the pharmacies identified in its price comparisons. All trademarks, brands, logos and copyright images are property of their respective owners and rights holders and are used solely to represent the products of these rights holders. This information is for informational purposes only and is not meant to be a substitute for professional medical advice, diagnosis or treatment. GoodRx is not offering advice, recommending or endorsing any specific prescription drug, pharmacy or other information on the site. GoodRx provides no warranty for any of the pricing data or other information. Please seek medical advice before starting, changing or terminating any medical treatment.